No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
Associations Between Hearing Performance and Physiological Measures - An Overview and Outlook
Abstract
The current paper summarises the research investigating associations between physiological data and hearing performance. An overview of state-of-the-art research and literature is given as well as promising directions for associations between physiological data and data regarding hearing loss and hearing performance. The physiological parameters included in this paper are: electrodermal activity, heart rate variability, blood pressure, blood oxygenation and respiratory rate. Furthermore, the environmental and behavioural measurements of physical activity and body mass index, alcohol consumption and smoking have been included. So far, only electrodermal activity and heart rate variability are physiological signals simultaneously associated with hearing loss or hearing performance. Initial findings suggest blood pressure and respiratory rate to be the most promising physiological measures that relate to hearing loss and hearing performance.
... / Other 3 4 These will include ratings of HA benefit and self/reporting of noise exposure that could lead to temporary or permanent threshold shift events Biosensors integrated in a commercially available wristband. The biosensors collect physiological data associated with listening effort, i.e. heart rate, respiratory rate and pulse (40,41). Training on how to use the mobile application and biosensors. ...
Introduction
The holistic management of hearing loss (HL) requires an understanding of factors that predict hearing aid (HA) use and benefit beyond the acoustics of listening environments. Although several predictors have been identified, no study has explored the role of audiological, cognitive, behavioural and physiological data nor has any study collected real-time HA data. This study will collect ‘big data’, including retrospective HA logging data, prospective clinical data and real-time data via smart HAs, a mobile application and biosensors. The main objective is to enable the validation of the EVOTION platform as a public health policy-making tool for HL.
Methods and analysis
This will be a big data international multicentre study consisting of retrospective and prospective data collection. Existing data from approximately 35 000 HA users will be extracted from clinical repositories in the UK and Denmark. For the prospective data collection, 1260 HA candidates will be recruited across four clinics in the UK and Greece. Participants will complete a battery of audiological and other assessments (measures of patient-reported HA benefit, mood, cognition, quality of life). Patients will be offered smart HAs and a mobile phone application and a subset will also be given wearable biosensors, to enable the collection of dynamic real-life HA usage data. Big data analytics will be used to detect correlations between contextualised HA usage and effectiveness, and different factors and comorbidities affecting HL, with a view to informing public health decision-making.
Ethics and dissemination
Ethical approval was received from the London South East Research Ethics Committee (17/LO/0789), the Hippokrateion Hospital Ethics Committee (1847) and the Athens Medical Center’s Ethics Committee (KM140670). Results will be disseminated through national and international events in Greece and the UK, scientific journals, newsletters, magazines and social media. Target audiences include HA users, clinicians, policy-makers and the general public.
Trial registration number
NCT03316287 ; Pre-results.
ResearchGate has not been able to resolve any references for this publication.